University of Utah Health Sciences Center Salt Lake City UT.
J Am Heart Assoc. 2024 Nov 5;13(21):e036520. doi: 10.1161/JAHA.124.036520. Epub 2024 Oct 22.
Ambulatory ECG (AECG) monitoring is pivotal to the diagnosis of arrhythmias and can be performed with near "real-time" notification of abnormalities. There are limited data on the relative benefit of real-time monitoring compared with traditional Holter monitoring.
This is a retrospective observational analysis of University of Utah Health patients who underwent ambulatory ECG studies from 2010 to 2022. The study cohort was stratified by patients with an ambulatory ECG that provides real-time event notification (non-Holter) versus those who do not (Holter). The outcomes were cardiac implantable electronic device procedure, ablation procedure, emergency department/hospitalization visit, and initiation of anticoagulation out to 6 months. We identified 20 259 patients, 16 650 with non-Holter studies and 3609 with Holter studies. Holter patients were younger (mean 52 versus 55, <0.001), more often women (60.2% versus 57%, <0.001), and had lower mean CHADS-VASc scores (1.7 versus 2.1, <0.001). The median time to ablation procedure was 74 versus 72 (=0.5), for Holter versus non-Holter, respectively. Median days to new cardiac implantable electronic device implantation was 54 days versus 52 (=0.6); initiation of anticoagulation among patients not already treated was 42 versus 31 days (=0.03). Time to first emergency department visit or hospitalization was 63 versus 57 (=0.6). In multivariable models, there were no significant differences in time to intervention between Holter and non-Holter for each outcome.
Real-time monitoring demonstrates mixed results in terms of reducing time to intervention, with the significant benefit limited to oral anticoagulation initiation. It is time to revisit clinical scenarios where real-time ambulatory monitoring may not improve health care efficiency.
动态心电图(AECG)监测对心律失常的诊断至关重要,并且可以实现异常情况的近乎“实时”通知。与传统 Holter 监测相比,实时监测的相对益处数据有限。
这是对 2010 年至 2022 年期间在犹他大学健康中心接受动态心电图检查的患者进行的回顾性观察性分析。该研究队列根据接受提供实时事件通知的动态心电图检查的患者(非 Holter)与未接受此类检查的患者(Holter)进行分层。主要转归为心脏植入式电子设备程序、消融程序、急诊/住院就诊和在 6 个月内开始抗凝治疗。我们确定了 20259 例患者,其中 16650 例患者进行了非 Holter 检查,3609 例患者进行了 Holter 检查。Holter 组患者更年轻(平均年龄 52 岁比 55 岁,<0.001),更多为女性(60.2%比 57%,<0.001),平均 CHADS-VASc 评分较低(1.7 比 2.1,<0.001)。消融程序的中位时间分别为 Holter 组 74 天和非 Holter 组 72 天(=0.5)。新植入心脏植入式电子设备的中位时间分别为 Holter 组 54 天和非 Holter 组 52 天(=0.6);未接受抗凝治疗的患者开始抗凝治疗的中位时间分别为 Holter 组 42 天和非 Holter 组 31 天(=0.03)。首次急诊就诊或住院的中位时间分别为 Holter 组 63 天和非 Holter 组 57 天(=0.6)。多变量模型中,Holter 组和非 Holter 组在每种转归的干预时间方面均无显著差异。
实时监测在减少干预时间方面的效果喜忧参半,其显著获益仅限于口服抗凝剂的启动。现在是重新审视实时动态监测可能不会提高医疗保健效率的临床情况的时候了。